| 4OHT | 4-hydroxytamoxifen |
| AhR | Aryl hydrocarbon receptor |
| AKT | Protein kinase B |
| AMPK | AMP-activated protein kinase |
| ARNT | Aryl hydrocarbon receptor nuclear translocator |
| CYP | Cytochrome P450 |
| DM | Diabetes mellitus |
| EGFR | Epidermal growth factor receptor |
| FGF21 | Fibroblast growth factor 21 |
| FICZ | 6-Formylindolo[3,2-b]carbazole |
| GDM | Gestational diabetes mellitus |
| GIP | glucose-dependent insulinotropic polypeptide |
| GLP-1 | Glucagon-like peptide-1 |
| GLUTs | Sodium-independent glucose transporters |
| GR | Glucocorticoid receptor |
| HIF-1 | Hypoxia-inducible factor-1 |
| IRs | Insulin receptors |
| IRS | Insulin receptor substrates |
| MAPK | Mitogen-activated protein kinases |
| mTORC1 | Mammalian target of rapamycin complex 1 |
| NAFLD | Non-alcoholic fatty liver disease |
| Nrf2 | NF-E2 p45-related factor |
| PAHs | Polycyclic aromatic hydrocarbons |
| PCOS | Polycystic ovary syndrome |
| PI3K | Phosphoinositide-3-kinase |
| PKC | Protein kinase C |
| PPARα | Peroxisome proliferator-activated receptor α |
| PPI | Proton pump inhibitor |
| PXR | Pregnane X receptor |
| S1P | Sphingosine-1-phosphate |
| SGLTs | Sodium-dependent glucose transporters |
| T1DM | Type 1 diabetes mellitus |
| T2DM | Type 2 diabetes mellitus |
| TADs | Transcriptional activation domains |
| TCDD | 2,3,7,8-tetrachlorodibenzodioxin |
| TDO | Tryptophan-2,3-dioxygenase |
| TSP-1 | Thrombospondin-1 |
| UV | Ultraviolet |
| VISTA | V-domain Ig suppressor of T cell activation |
| XREs | Xenobiotic response elements |